Assessment of viral genotype impact to the cost-effectiveness and overall costs of care for peg-interferon-2α + ribavirine treated chronic hepatitis C patients

Hepatitis Monthly

Volumn 13, Issue 6, 2013, Pages 1-10

  Mihajlo, Jakovljevic B ^a   Zeljko, Mijailovic D ^b   Biljana, Popovska Jovicic D ^b   Predrag, Canovic S ^b   Olgica, Gajovic M ^b   Mirjana, Jovanovic R ^b   Dejan, Petrovic S ^b   Olivera, Milovanovic Z ^a   Natasa, Djordjevic D ^a  

^a University of Kragujevac Medical Faculty   (Serbia)

^b University Clinical Center Kragujevac   (Serbia)

Author keywords

Chronic; Cost benefit analysis; Hepatitis C; Interferons; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GLOBULIN; PEGINTERFERON ALPHA2A; PLASMA PROTEIN; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; BLOOD BIOCHEMISTRY; CHRONIC HEPATITIS C; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DISEASE TRANSMISSION; FEMALE; FIBROSIS; FOLLOW UP; GENOTYPE; GENOTYPING TECHNIQUE; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HISTOPATHOLOGY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 85006226925     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.6750     Document Type: Article

References (33)

1. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39(4):1147-71.
2. Pecic V, Stankovic-Djordjevic D, Nestorovic M, Radojkovic M, Marjanovic H, Ilic B, et al. Hepatitis C virus-related hepatocellular carcinoma and liver cirrhosis. J Buon. 2011;16(2):277-81.
3. Chevaliez S, Pawlotsky JM. Hepatitis C virus: virology, diagnosis and management of antiviral therapy. World J Gastroenterol. 2007;13(17):2461-6.
4. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature. 2005;436(7053):953-60.
5. Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Pivert A, Goudeau A, et al. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol. 2007;13(17):2416-26.
6. Lee CM, Hung CH, Lu SN, Changchien CS. Hepatitis C virus genotypes: clinical relevance and therapeutic implications. Chang Gung Med J. 2008;31(1):16-25.
7. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000;13(2):223-35.
8. Kuljic-Kapulica N, Jovanovic D, Savic D, Ristanovic E, Nozic D, Rajic R. [Therapy of chronic hepatitis C--virologic response monitoring]. Vojnosanit Pregl. 2010;67(11):923-7.
9. Briggs A, Shiell A. Interferon-alpha in hepatitis C. Dosage, costs and benefits. Pharmacoeconomics. 1996;10(3):205-9.
10. Garcia de Ancos JL, Roberts JA, Dusheiko GM. An economic evaluation of the costs of alpha-interferon treatment of chronic active hepatitis due to hepatitis B or C virus. J Hepatol. 1990;11 Suppl 1:S11-8.
11. Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess. 2011;15(17):1-12, 1-210.
12. Solomon M, Bonafede M, Pan K, Wilson K, Beam C, Chakravarti P, et al. Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients. Dig Dis Sci. 2011;56(10):3024-31.
13. Wong JB. Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness. Acta Gastroenterol Belg. 1998;61(2):238-42.
14. Nikolic P, Jemuovic L, Delic D, Korac M, Boricic I. Treatment of chronic hepatitis C with interferon alpha – our results. Acta Infectologica Yugoslavica. 2000;5:1-9.
15. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42(4):962-73.
16. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175-91.
17. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006;130(4):1086-97.
18. Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O. Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up. J Viral Hepat. 2012;19(2):e97-104.
19. Jacobs P, Fassbender K. The measurement of indirect costs in the health economics evaluation literature. A review. Int J Technol Assess Health Care. 1998;14(4):799-808.
20. Matsuura K, Tanaka Y, Hasegawa I, Ohno T, Tokuda H, Kurbanov F, et al. Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients. J Clin Microbiol. 2009;47(2):385-9.
21. Serbia IoPHo. Health statistical yearbook of Republic of Serbia 2010. Belgrade: Institute of Public Health of Serbia; 2010.
22. Annemans L. Health economics for non-economists: an introduction to the concepts, methods and pitfalls of health economic evaluations. Belgium: Academia Press; 2008.
23. Gajic-Stevanovic M, Vuksa A, Zivkovic S, Teodorovic N. Cost of primary health care in the Republic of Serbia for the period 2006-2008. Serbian Dental J. 2010;57:86-97.
24. Gerkens S, Nechelput M, Annemans L, Peraux B, Mouchart M, Beguin C, et al. A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C. J Viral Hepat. 2007;14(8):523-36.
25. O'Hagan A, Stevens JW, Montmartin J. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. Pharmacoeconomics. 2000;17(4):339-49.
26. Carlsson T, Quist A, Weiland O. Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods. J Med Virol. 2008;80(5):803-7.
27. Marcellin P, Reau N, Ferenci P, Hadziyannis S, Messinger D, Tatsch F, et al. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J Hepatol. 2012.
28. Romeo JM, Ulrich PP, Busch MP, Vyas GN. Analysis of hepatitis C virus RNA prevalence and surrogate markers of infection among seropositive voluntary blood donors. Hepatology. 1993;17(2):188-95.
29. Singal AK, Anand BS. Tailoring treatment duration to 12 to 16 weeks in hepatitis C genotype 2 or 3 with rapid virologic response: systematic review and meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2010;44(8):583-7.
30. Glied S. Mandates and the affordability of health care. Inquiry. 2009;46(2):203-14.
31. Noble SM, Hollingworth W, Tilling K. Missing data in trial-based cost-effectiveness analysis: the current state of play. Health Econ. 2012;21(2):187-200.
32. Su J, Brook RA, Kleinman NL, Corey-Lisle P. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology. 2010;52(2):436-42.
33. Shah NM, Brieger WR, Peters DH. Can interventions improve health services from informal private providers in low and middle-income countries?: a comprehensive review of the literature. Health Policy Plan. 2011;26(4):275-87.